Derek Barratt
Overview
Explore the profile of Derek Barratt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johannes J, Balazs A, Barratt D, Bista M, Chuba M, Cosulich S, et al.
J Med Chem
. 2024 Dec;
67(24):21717-21728.
PMID: 39655996
PARP inhibitors have attracted considerable interest in drug discovery due to the clinical success of first-generation agents such as olaparib, niraparib, rucaparib, and talazoparib. Their success lies in their ability...
2.
Christopher J, Breckels L, Crook O, Vazquez-Chantada M, Barratt D, Lilley K
Mol Cell Proteomics
. 2024 Dec;
24(1):100888.
PMID: 39617061
Cells have many protective mechanisms against background levels of ionizing radiation orchestrated by molecular changes in expression, post-translational modifications, and subcellular localization. Radiotherapeutic treatment in oncology attempts to overwhelm such...
3.
Kettle J, Bagal S, Barratt D, Bodnarchuk M, Boyd S, Braybrooke E, et al.
J Med Chem
. 2023 Jul;
66(13):9147-9160.
PMID: 37395055
The glycine to cysteine mutation at codon 12 of Kirsten rat sarcoma (KRAS) represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based...
4.
Goldberg F, Ting A, Beattie D, Lamont G, Fallan C, Finlay M, et al.
ACS Med Chem Lett
. 2022 Aug;
13(8):1295-1301.
PMID: 35978693
The DNA-PK complex is activated by double-strand DNA breaks and regulates the non-homologous end-joining repair pathway; thus, targeting DNA-PK by inhibiting the DNA-PK catalytic subunit (DNA-PKcs) is potentially a useful...
5.
Kantae V, Polanski R, Lewis H, Haider A, Barratt D, Srinivasan B
ACS Chem Biol
. 2022 Jul;
17(8):2366-2376.
PMID: 35881961
Covalent inhibition is a valuable modality in drug discovery because of its potential ability in decoupling pharmacokinetics from pharmacodynamics by prolonging the residence time of the drug on the target...
6.
Johannes J, Balazs A, Barratt D, Bista M, Chuba M, Cosulich S, et al.
J Med Chem
. 2021 Sep;
64(19):14498-14512.
PMID: 34570508
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually due to...
7.
Khurana P, McWilliams L, Wingfield J, Barratt D, Srinivasan B
SLAS Discov
. 2021 Mar;
26(5):684-697.
PMID: 33783249
Target engagement by small molecules is necessary for producing a physiological outcome. In the past, a lot of emphasis was placed on understanding the thermodynamics of such interactions to guide...
8.
McAulay K, Hoyt E, Thomas M, Schimpl M, Bodnarchuk M, Lewis H, et al.
J Am Chem Soc
. 2020 May;
142(23):10358-10372.
PMID: 32412754
With a resurgence in interest in covalent drugs, there is a need to identify new moieties capable of cysteine bond formation that are differentiated from commonly employed systems such as...
9.
Smith G, Barratt D, Rowlinson R, Nickson J, Tonge R
Proteomics
. 2005 May;
5(9):2315-8.
PMID: 15887186
There is an increasing interest in analysing the human urinary proteome in the search for biomarkers. However, despite the ease of its collection, urine is a difficult fluid to analyse...